drugset / Trial / NCT01925092
Mifepristone in Children With Refractory Cushing's Disease
Phase 3
Withdrawn
Corcept Therapeutics
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collab
NaSingle-groupOpen-labelTreatment
Summary
Study objectives are to obtain safety, pharmacokinetic, and pharmacodynamic data on the effect of mifepristone on glucose metabolism, body weight and the growth-hormone-IGF in children with refractory Cushing's disease.
Timeline
- Start
- 2013-08
- Primary completion
- 2016-12
- Completion
- —
Outcome
Outcome not reported
Stopped (Enrollment): “Lack of enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mifepristone | Small molecule | — | — |